🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementDay 3 on sema and I feel like death warmed over — need advice

Day 3 on sema and I feel like death warmed over — need advice

roxy_nash Sat, Aug 16, 2025 at 7:33 AM 50 replies 2,150 viewsPage 1 of 10
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Aug 16, 2025 at 7:33 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

What would genuinely help is knowing what distinguishes the nausea you can titrate through from the nausea that means stop.

Numbers rather than impressions, if you have them.

15 10josh_phd_bmore, roxy_nash, tony_orlando and 12 others
Reply Quote Save Share Report
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Aug 16, 2025 at 7:40 AM#2

This one has a reasonably settled answer, so here it is. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: Aug 16, 2025 at 11:40 AM
14 9sarah_TO, wendy_avl, jason_paloalto and 11 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Aug 16, 2025 at 7:47 AM#3
JessicaH_TX said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

Last edited: Aug 16, 2025 at 12:47 PM
13 8Dr.NutriCornell, pam_stl, wei_SG and 10 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
Aug 16, 2025 at 7:54 AM#4
roxy_nash said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Can confirm the pattern roxy_nash describes. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

12 7maya_sedona, stefan_berlin, Dr.EM_Chicago and 9 others
Reply Quote Save Share Report
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Aug 16, 2025 at 8:32 AM#5

Adding the clinical framing, because it changes how the question reads. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

11 6kevin_tulsa, Dr.PainCLE, mike_mealprep and 8 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register